PRESENTATION

Q3 2023 — Presentation

Q3 2023PDF · 30 pages665 KB
Danaher
Corporation
Third Quarter 2023 Earnings Release
October 24, 2023

-- 1 of 30 --

2
Forward Looking Statements
Statements in this presentation that are not strictly historical, including any statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-
looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ
materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among
other things, potential future, adverse impacts on our business, results of operations and financial condition related to the COVID-19 pandemic , the impact of our debt obligations on our
operations and liquidity, deterioration of or instability in the economy, the markets we serve and the financial markets, uncertainties relating to national laws or policies, including laws or policies to
protect or promote domestic interests and/or address foreign competition, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully
market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and
regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, our
ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions (including the pending
acquisition of Abcam plc) and strategic investments and successfully complete divestitures and other dispositions, our ability to integrate the businesses we acquire and achieve the anticipated
growth, synergies and other benefits of such acquisitions, contingent liabilities and other risks relating to acquisitions, investments, strategic relationships and divestitures (including tax-related
and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs), security breaches or other disruptions of our information technology systems or violations of data privacy
laws, the impact of our restructuring activities on our ability to grow, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes
in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation and other contingent liabilities including intellectual property and environmental, health
and safety matters, the rights of the United States government with respect to our production capacity in times of national emergency or with respect to intellectual property/production capacity
developed using government funding, risks relating to product, service or software defects, product liability and recalls, risks relating to fluctuations in the cost and availability of the supplies we
use (including commodities) and labor we need for our operations, our relationships with and the performance of our channel partners, uncertainties relating to collaboration arrangements with
third-parties, the impact of deregulation on demand for our products and services, the impact of climate change, legal or regulatory measures to address climate change and our ability to address
stakeholder expectations relating to climate change, labor matters and our ability to recruit, retain and motivate talented employees representing diverse backgrounds, experiences and skill sets,
non-U.S. economic, political, legal, compliance, social and business factors (including the impact of military conflicts), disruptions relating to man-made and natural disasters, pension plan and
healthcare costs, inflation and the impact of our By-law exclusive forum provisions. Additional information regarding the factors that may cause actual results to differ materially from these forward-
looking statements is available in our SEC filings, including our 2022 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the third quarter of 2023. These forward-looking
statements speak only as of the date of this presentation (October 24, 2023) and except to the extent required by applicable law, the Company does not assume any obligation to update or revise
any forward-looking statement, whether as a result of new information, future events and developments or otherwise.
With respect to the non-GAAP financial measures referenced in the following presentation, definitions and the accompanying information required by SEC Regulation G can be found in this
presentation or in the “Investors” section of Danaher’s web site, www.danaher.com, under the heading “Financial Reports” and subheading “Quarterly Earnings.” In addition, in addressing various
financial metrics the presentation describes certain of the more significant factors that impacted year-over-year performance. For additional factors that impacted year-over-year performance,
please refer to our earnings release and the other related presentation materials supplementing today’s call, all of which are available in the “Investors” section of Danaher’s web site under the
heading “Financial Reports” and subheading “Quarterly Earnings,” as well as our third quarter Form 10-Q. All references in this presentation (1) to financial metrics relate only to the continuing
operations of Danaher’s business, unless otherwise noted; and (2) to “growth” or other period-to-period changes refer to year-over-year comparisons unless otherwise indicated. We may also
describe certain products and devices which have applications submitted and pending for certain regulatory approvals.

-- 2 of 30 --

3
Third Quarter 2023 Performance Summary
Throughout this presentation, with respect to revenue performance, for the definitions of "Acquisitions," “Core,” and “FX,” please refer to the accompanying information required by Regulation G, located at the end of this
presentation and on the "Investors" section of Danaher's website.
Revenue
-10.5%
Core -11.5%
Acquisitions +0.5%
FX +0.5%
Adjusted Diluted Net Earnings Per
Common Share
-21.1%
($ millions)

-- 3 of 30 --

4
Third Quarter 2023 Performance Summary
Throughout this presentation when referred to in connection with operating profit margins, “Acquisitions” refers to the impact of businesses owned for less than one year or disposed of during such period and not treated as
discontinued operations, “Other” refers to the impact of impairment and charges incurred in 2023 and costs incurred in 2023 related to preparation for the separation of the Company's Environmental and Applied Solutions
business; for further description of these items, please refer to the accompanying information required by Regulation G, located at the end of this presentation and on the "Investors" section of Danaher's website.
Free Cash Flow Performance	Operating Profit Margin
-540 BPS
Core -470 bps
Acquisitions -5 bps
Other -65 bps
-24.5%
($ millions)

-- 4 of 30 --

5
Third Quarter 2023: Biotechnology
Revenue 	Operating Profit Margin
-860 BPS
Core -865 bps
Acquisitions +5 bps
-19.0%
Core -21.0%
Acquisitions +0.5%
FX +1.5%
($ millions)

-- 5 of 30 --

6
Third Quarter 2023: Life Sciences
Revenue 	Operating Profit Margin
-220 BPS
Core -195 bps
Acquisitions -25 bps
-1.0%
($ millions)
Core -2.5%
Acquisitions +1.0%
FX +0.5%

-- 6 of 30 --

7
Third Quarter 2023: Diagnostics
Revenue 	Operating Profit Margin
-450 BPS
Core -445 bps
Acquisitions -5 bps
-16.0%
($ millions)
Core -15.5%
FX -0.5%

-- 7 of 30 --

8
Guidance

-- 8 of 30 --

9
Q&A

-- 9 of 30 --



-- 10 of 30 --

DANAHER CORPORATION
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
AND SUPPLEMENTAL FORWARD-LOOKING INFORMATION
THREE AND NINE-MONTH PERIODS ENDED SEPTEMBER 29, 2023 AND SEPTEMBER 30, 2022

-- 11 of 30 --

TABLE OF CONTENTS
Page
1 Sales (Decline) Growth by Segment, Core Sales (Decline) Growth by Segment and Base Business Core Sales (Decline) Growth by Segment
2 Forecasted Core Sales (Decline) Growth, Base Business Core Sales (Decline) Growth and Adjusted Operating Profit Margin
3 Segment Sales, Operating Profit and Adjusted Operating Profit
4 Net Earnings, Operating Profit, Adjusted EBITDA, Net Earnings Margin, Operating Profit Margin and Adjusted EBITDA Margin
8 Other Non-GAAP Adjusted P&L Measures
14 Average and Adjusted Average Common Stock and Common Equivalent Diluted Shares Outstanding
15 Operating Profit Margins and Year-Over-Year Core Operating Profit Margin Changes
16 Cash Flow, Free Cash Flow, Operating Cash Flow to Net Earnings Ratio and Free Cash Flow to Net Earnings Conversion Ratio
17 Statement Regarding Non-GAAP Measures
FORWARD-LOOKING STATEMENTS DISCLOSURE
Statements in this document that are not strictly historical, including any statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-
looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ
materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include,
among other things, potential future, adverse impacts on our business, results of operations and financial condition related to the COVID-19 pandemic, the impact of our debt obligations on our
operations and liquidity, deterioration of or instability in the economy, the markets we serve and the financial markets, uncertainties relating to national laws or policies, including laws or policies
to protect or promote domestic interests and/or address foreign competition, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully
market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and
regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof,
our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions (including the pending
acquisition of Abcam plc) and strategic investments and successfully complete divestitures and other dispositions, our ability to integrate the businesses we acquire and achieve the anticipated
growth, synergies and other benefits of such acquisitions, contingent liabilities and other risks relating to acquisitions, investments, strategic relationships and divestitures (including tax-related
and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs), security breaches or other disruptions of our information technology systems or violations of data privacy
laws, the impact of our restructuring activities on our ability to grow, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes
in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation and other contingent liabilities including intellectual property and environmental,
health and safety matters, the rights of the United States government with respect to our production capacity in times of national emergency or with respect to intellectual property/production
capacity developed using government funding, risks relating to product, service or software defects, product liability and recalls, risks relating to fluctuations in the cost and availability of the
supplies we use (including commodities) and labor we need for our operations, our relationships with and the performance of our channel partners, uncertainties relating to collaboration
arrangements with third-parties, the impact of deregulation on demand for our products and services, the impact of climate change, legal or regulatory measures to address climate change and
our ability to address stakeholder expectations relating to climate change, labor matters and our ability to recruit, retain and motivate talented employees representing diverse backgrounds,
experiences and skill sets, non-U.S. economic, political, legal, compliance, social and business factors (including the impact of military conflicts), disruptions relating to man-made and natural
disasters, pension plan and healthcare costs, inflation and the impact of our By-law exclusive forum provisions. Additional information regarding the factors that may cause actual results to differ
materially from these forward-looking statements is available in our SEC filings, including our 2022 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the third quarter of 2023.
These forward-looking statements speak only as of the date of this document (October 23, 2023) and except to the extent required by applicable law, the Company does not assume any
obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

-- 12 of 30 --

% Change Three-Month Period Ended September 29, 2023 vs. Comparable 2022 Period
Segments
Total Company Biotechnology Life Sciences Diagnostics
Environmental &
Applied
Solutions
Total sales (decline) growth (GAAP) (10.5) % (19.0) % (1.0) % (16.0) % 3.5 %
Impact of:
Acquisitions/divestitures (0.5) % (0.5) % (1.0) % — % (0.5) %
Currency exchange rates (0.5) % (1.5) % (0.5) % 0.5 % (2.0) %
Core sales (decline) growth (non-GAAP) (11.5) % (21.0) % (2.5) % (15.5) % 1.0 %
Impact of COVID-19 related testing, vaccines and therapeutics 8.5 % +Mid-single
digit +Up slightly +Low-twenties — %
Base business core sales (decline) growth (non-GAAP) (3.0) % -Mid-teens -Low-single
digit +Mid-single
digit 1.0 %
% Change Nine-Month Period Ended September 29, 2023 vs. Comparable 2022 Period
Segments
Total Company Biotechnology Life Sciences Diagnostics
Environmental &
Applied
Solutions
Total sales (decline) growth (GAAP) (8.0) % (17.0) % 2.5 % (13.0) % 3.5 %
Impact of:
Acquisitions/divestitures (0.5) % — % (1.0) % — % (0.5) %
Currency exchange rates 1.0 % 0.5 % 1.0 % 1.5 % — %
Core sales (decline) growth (non-GAAP) (7.5) % (16.5) % 2.5 % (11.5) % 3.0 %
Impact of COVID-19 related testing, vaccines and therapeutics 9.0 % +High-single
digit +Low-single
digit +Low-twenties — %
Base business core sales growth (decline) (non-GAAP) 1.5 % -High-single
digit +Mid-single
digit +High-single
digit 3.0 %
Note: We expect overall demand for the Company’s COVID-19 related products to continue moderating as the pandemic has evolved toward endemic status. We believe certain demand for the
Company’s products that support COVID-19 related vaccines and therapeutics (including initiatives that seek to prevent or mitigate similar, future pandemics) and COVID-19 testing will continue,
though that demand will likely be uncertain and will vary from period to period. At the beginning of 2022, the Company believed that on a relative basis, the level of ongoing demand for products
supporting COVID-19 testing would be subject to more fluctuations in demand than the level of demand for products supporting COVID-19 related vaccines and therapeutics, due in part to
expected COVID-19 case levels, vaccination rates and use of therapies. However, as a result of lower vaccination rates and the spread of less severe variants of the virus, 2022 demand for the
Company’s products supporting COVID-19 related vaccines and therapeutics fluctuated and declined more than anticipated at the beginning of the year. Therefore, beginning with the first
quarter of 2023, we have revised the definition of “base business core sales growth” on a basis that not only excludes revenues related to COVID-19 testing but also excludes revenues from
products that support COVID-19 related vaccines and therapeutics. We believe this adjusted definition of “base business core sales growth” provides more useful information to investors by
facilitating period-to-period comparisons of our financial performance and identifying underlying growth trends in the Company’s business that otherwise may be obscured by fluctuations in
demand for COVID-19 related products.
DANAHER CORPORATION
Sales (Decline) Growth by Segment, Core Sales (Decline) Growth by Segment and Base Business Core Sales (Decline) Growth by Segment
1

-- 13 of 30 --

The Company provides forecasted sales only on a non-GAAP basis because of the difficulty in estimating the other components of GAAP revenue, such as
currency translation, acquisitions and divested product lines. Additionally, we do not reconcile adjusted operating profit margin (or components thereof) to the
comparable GAAP measures because of the difficulty in estimating the other components (in addition to items identified in the prior sentence) such as investment
gains and losses, impairments and separation costs, which would be reflected in any forecasted GAAP operating profit. On September 30, 2023, the Company
completed the separation of its former Environmental & Applied Solutions business by distributing to Danaher stockholders on a pro rata basis all of the issued and
outstanding common stock of Veralto Corporation (“Veralto”). The reporting of Veralto as a discontinued operation will be reflected in the Company’s future filings,
but in no way revises or restates any Consolidated Statements of Earnings for any period previously filed with the U.S. Securities and Exchange Commission.
% Change Three-Month
Period Ending December
31, 2023 vs. Comparable
2022 Period
% Change Year Ending
December 31, 2023 vs.
Comparable 2022 Period
Core sales decline from continuing operations reflecting Veralto as a discontinued operation (non-GAAP) -High-teens -Low-double digit
Impact of COVID-19 related testing, vaccines and therapeutics +Low-double digit +Low-double digit
Base business core sales decline from continuing operations reflecting Veralto as a discontinued operation (non-
GAAP) -Mid-single digit -Down slightly
Three-Month Period
Ending December 31,
2023 Year Ending
December 31, 2023
Adjusted operating profit margin reflecting Veralto as a discontinued operation (non-GAAP) ~28.0% ~29.0%
DANAHER CORPORATION
Forecasted Core Sales (Decline) Growth, Base Business Core Sales (Decline) Growth and Adjusted Operating Profit Margin
2

-- 14 of 30 --

Sales (GAAP)
Biotechnology $ 1,664 $ 2,053 $ 5,413 $ 6,535
Life Sciences 1,706 1,723 5,211 5,090
Diagnostics 2,254 2,679 6,861 7,884
Environmental & Applied Solutions 1,249 1,208 3,712 3,593
Total Company $ 6,873 $ 7,663 $ 21,197 $ 23,102
Operating Profit (GAAP)
Biotechnology $ 417 $ 691 $ 1,493 $ 2,315
Life Sciences 313 354 974 1,022
Diagnostics 539 761 1,640 2,447
Environmental & Applied Solutions 286 286 887 829
Other (117) (77) (333) (221)
Total Company $ 1,438 $ 2,015 $ 4,661 $ 6,392
Amortization of Intangible Assets (GAAP)
Biotechnology $ 214 $ 197 $ 649 $ 616
Life Sciences 104 103 313 315
Diagnostics 49 50 149 151
Environmental & Applied Solutions 12 11 36 38
Total Company $ 379 $ 361 $ 1,147 $ 1,120
Other Operating Profit Adjustments 1
Biotechnology $ — $ — $ 42 $ 14
Life Sciences — — — 24
Diagnostics — — — 3
Environmental & Applied Solutions 6 — 12 10
Other 36 — 101 1
Total Company $ 42 $ — $ 155 $ 52
Adjusted Operating Profit (non-GAAP) 2
Biotechnology $ 631 $ 888 $ 2,184 $ 2,945
Life Sciences 417 457 1,287 1,361
Diagnostics 588 811 1,789 2,601
Environmental & Applied Solutions 304 297 935 877
Other (81) (77) (232) (220)
Total Company $ 1,859 $ 2,376 $ 5,963 $ 7,564
Three-Month Period Ended Nine-Month Period Ended
September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022
1 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments.
2 Adjusted Operating Profit (non-GAAP) is defined as operating profit (GAAP) plus amortization of intangible assets (GAAP) plus (minus) Other Operating Profit Adjustments (as defined).
DANAHER CORPORATION
Segment Sales, Operating Profit and Adjusted Operating Profit
($ in millions)
3

-- 15 of 30 --

Three-Month Period Ended September 29, 2023
Biotechnology Life Sciences Diagnostics
Environmental &
Applied
Solutions Other Total Company
Net Earnings (GAAP) $ 1,129
Interest, Net (6)
Other Nonoperating (Income) Expense 47
Income Taxes 268
Operating Profit (GAAP) $ 417 $ 313 $ 539 $ 286 $ (117) $ 1,438
Other Operating Profit Adjustments 1 — — — 6 36 42
Depreciation 40 31 93 9 2 175
Amortization of Intangible Assets 214 104 49 12 — 379
Adjusted EBITDA (Non-GAAP) $ 671 $ 448 $ 681 $ 313 $ (79) $ 2,034
Interest, Net 6
Other Nonoperating Income (Expense) (47)
Income Taxes (268)
Other Operating Profit Adjustments 1 (42)
Depreciation (175)
Amortization of Intangible Assets (379)
Net Earnings (GAAP) $ 1,129
Sales (GAAP) $ 1,664 $ 1,706 $ 2,254 $ 1,249 $ 6,873
Net Earnings Margin (GAAP) 16.4 %
Operating Profit Margin (GAAP) 25.1 % 18.3 % 23.9 % 22.9 % 20.9 %
Adjusted EBITDA Margin (Non-GAAP) 3 40.3 % 26.3 % 30.2 % 25.1 % 29.6 %
1 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments.
3 Adjusted EBITDA Margin (Non-GAAP) is defined as Adjusted EBITDA (Non-GAAP) divided by sales.
DANAHER CORPORATION
Net Earnings, Operating Profit, Adjusted EBITDA, Net Earnings Margin, Operating Profit Margin and Adjusted EBITDA Margin
($ in millions)
4

-- 16 of 30 --

Three-Month Period Ended September 30, 2022
Biotechnology Life Sciences Diagnostics
Environmental &
Applied
Solutions Other Total Company
Net Earnings (GAAP) $ 1,572
Interest, Net 33
Other Nonoperating (Income) Expense 51
Income Taxes 359
Operating Profit (GAAP) $ 691 $ 354 $ 761 $ 286 $ (77) $ 2,015
Other Operating Profit Adjustments 1 — — — — — —
Depreciation 40 29 98 10 2 179
Amortization of Intangible Assets 197 103 50 11 — 361
Adjusted EBITDA (Non-GAAP) $ 928 $ 486 $ 909 $ 307 $ (75) $ 2,555
Interest, Net (33)
Other Nonoperating Income (Expense) (51)
Income Taxes (359)
Other Operating Profit Adjustments 1 —
Depreciation (179)
Amortization of Intangible Assets (361)
Net Earnings (GAAP) $ 1,572
Sales (GAAP) $ 2,053 $ 1,723 $ 2,679 $ 1,208 $ 7,663
Net Earnings Margin (GAAP) 20.5 %
Operating Profit Margin (GAAP) 33.7 % 20.5 % 28.4 % 23.7 % 26.3 %
Adjusted EBITDA Margin (Non-GAAP) 3 45.2 % 28.2 % 33.9 % 25.4 % 33.3 %
1 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments.
3 Adjusted EBITDA Margin (Non-GAAP) is defined as Adjusted EBITDA (Non-GAAP) divided by sales.
DANAHER CORPORATION
Net Earnings, Operating Profit, Adjusted EBITDA, Net Earnings Margin, Operating Profit Margin and Adjusted EBITDA Margin
($ in millions)
5

-- 17 of 30 --

Nine-Month Period Ended September 29, 2023
Biotechnology Life Sciences Diagnostics
Environmental &
Applied
Solutions Other Total Company
Net Earnings (GAAP) $ 3,685
Interest, Net 22
Other Nonoperating (Income) Expense 52
Income Taxes 902
Operating Profit (GAAP) $ 1,493 $ 974 $ 1,640 $ 887 $ (333) $ 4,661
Other Operating Profit Adjustments 1 42 — — 12 101 155
Depreciation 119 92 282 29 4 526
Amortization of Intangible Assets 649 313 149 36 — 1,147
Adjusted EBITDA (Non-GAAP) $ 2,303 $ 1,379 $ 2,071 $ 964 $ (228) $ 6,489
Interest, Net (22)
Other Nonoperating Income (Expense) (52)
Income Taxes (902)
Other Operating Profit Adjustments 1 (155)
Depreciation (526)
Amortization of Intangible Assets (1,147)
Net Earnings (GAAP) $ 3,685
Sales (GAAP) $ 5,413 $ 5,211 $ 6,861 $ 3,712 $ 21,197
Net Earnings Margin (GAAP) 17.4 %
Operating Profit Margin (GAAP) 27.6 % 18.7 % 23.9 % 23.9 % 22.0 %
Adjusted EBITDA Margin (Non-GAAP) 3 42.5 % 26.5 % 30.2 % 26.0 % 30.6 %
1 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments.
3 Adjusted EBITDA Margin (Non-GAAP) is defined as Adjusted EBITDA (Non-GAAP) divided by sales.
DANAHER CORPORATION
Net Earnings, Operating Profit, Adjusted EBITDA, Net Earnings Margin, Operating Profit Margin and Adjusted EBITDA Margin
($ in millions)
6

-- 18 of 30 --

Nine-Month Period Ended September 30, 2022
Biotechnology Life Sciences Diagnostics
Environmental &
Applied
Solutions Other Total Company
Net Earnings (GAAP) $ 4,977
Interest, Net 135
Other Nonoperating (Income) Expense 158
Income Taxes 1,122
Operating Profit (GAAP) $ 2,315 $ 1,022 $ 2,447 $ 829 $ (221) $ 6,392
Other Operating Profit Adjustments 1 14 24 3 10 1 52
Depreciation 127 84 290 31 5 537
Amortization of Intangible Assets 616 315 151 38 — 1,120
Adjusted EBITDA (Non-GAAP) $ 3,072 $ 1,445 $ 2,891 $ 908 $ (215) $ 8,101
Interest, Net (135)
Other Nonoperating Income (Expense) (158)
Income Taxes (1,122)
Other Operating Profit Adjustments 1 (52)
Depreciation (537)
Amortization of Intangible Assets (1,120)
Net Earnings (GAAP) $ 4,977
Sales (GAAP) $ 6,535 $ 5,090 $ 7,884 $ 3,593 $ 23,102
Net Earnings Margin (GAAP) 21.5 %
Operating Profit Margin (GAAP) 35.4 % 20.1 % 31.0 % 23.1 % 27.7 %
Adjusted EBITDA Margin (Non-GAAP) 3 47.0 % 28.4 % 36.7 % 25.3 % 35.1 %
1 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments.
3 Adjusted EBITDA Margin (Non-GAAP) is defined as Adjusted EBITDA (Non-GAAP) divided by sales.
DANAHER CORPORATION
Net Earnings, Operating Profit, Adjusted EBITDA, Net Earnings Margin, Operating Profit Margin and Adjusted EBITDA Margin
($ in millions)
7

-- 19 of 30 --

Three-Month Period Ended September 29, 2023
Sales Cost of sales Gross profit
margin Operating
profit Operating
profit margin
Earnings
before
income taxes Income taxes
Net earnings
for calculation
of diluted
earnings per
common share
Diluted net
earnings per
common
share
Reported (GAAP) $ 6,873 $ (2,873) 58.2 % $ 1,438 20.9 % $ 1,397 $ (268) $ 1,129 I $ 1.51
Amortization of acquisition-related
intangible assets A — — — 379 5.5 379 379 0.51
Fair value net (gains) losses on
investments B — — — — — 48 48 0.06
Separation costs C — — — 36 0.5 36 36 0.05
Impairments and other charges D — — — 6 0.1 6 6 0.01
Tax effect of the above adjustments F (92) (92) (0.12)
Adjusted (Non-GAAP) $ 6,873 $ (2,873) 58.2 % $ 1,859 27.0 % $ 1,866 $ (360) $ 1,506 $ 2.02
Three-Month Period Ended September 29, 2023
Sales
Selling,
general and
administrative
expenses
Selling,
general and
administrative
expenses as a
% of sales
Research and
development
expenses
Research and
development
expenses as a
% of sales
Nonoperating
income
(expense), net
(excluding
interest)
Interest
income
(expense),
net
Reported (GAAP) $ 6,873 $ (2,145) (31.2) % $ (417) (6.1) % $ (47) $ 6
Amortization of acquisition-related
intangible assets A — 379 5.5 — — — —
Fair value net (gains) losses on
investments B — — — — — 48 —
Separation costs C — 36 0.5 — — — —
Impairments and other charges D — 6 0.1 — — — —
Adjusted (Non-GAAP) $ 6,873 $ (1,724) (25.1) % $ (417) (6.1) % $ 1 $ 6
DANAHER CORPORATION
Other Non-GAAP Adjusted P&L Measures
($ in millions, except per share data)
8

-- 20 of 30 --

Three-Month Period Ended September 30, 2022
Sales Cost of sales Gross profit
margin Operating
profit Operating
profit margin
Earnings
before
income taxes Income taxes
Net earnings
for calculation
of diluted
earnings per
common share
Diluted net
earnings per
common
share 4
Reported (GAAP) $ 7,663 $ (3,079) 59.8 % $ 2,015 26.3 % $ 1,931 $ (359) $ 1,551 I $ 2.10
Amortization of acquisition-related
intangible assets A — — — 361 4.7 361 361 0.48
Fair value net (gains) losses on
investments B — — — — — 64 64 0.09
Tax effect of the above adjustments F (84) (84) (0.11)
Discrete tax adjustments G (3) (3) —
MCPS "as if converted" H — — — — — — — 21 —
Adjusted (Non-GAAP) $ 7,663 $ (3,079) 59.8 % $ 2,376 31.0 % $ 2,356 $ (446) $ 1,910 $ 2.56
Three-Month Period Ended September 30, 2022
Sales
Selling,
general and
administrative
expenses
Selling,
general and
administrative
expenses as a
% of sales
Research and
development
expenses
Research and
development
expenses as
a % of sales
Nonoperating
income
(expense),
net
(excluding
interest)
Interest
income
(expense),
net
Reported (GAAP) $ 7,663 $ (2,149) (28.0) % $ (420) (5.5) % $ (51) $ (33)
Amortization of acquisition-related
intangible assets A — 361 4.7 — — — —
Fair value net (gains) losses on
investments B — — — — — 64 —
Adjusted (Non-GAAP) $ 7,663 $ (1,788) (23.3) % $ (420) (5.5) % $ 13 $ (33)
4 Each of the per share amounts above have been calculated assuming the Mandatory Convertible Preferred Stock (“MCPS”) had been converted into shares of common stock. Net earnings per diluted
common share amounts for the relevant three-month period may not add to the year-to-date amounts due to rounding.
DANAHER CORPORATION
Other Non-GAAP Adjusted P&L Measures
($ in millions, except per share data)
9

-- 21 of 30 --

Nine-Month Period Ended September 29, 2023
Sales Cost of sales Gross profit
margin Operating
profit Operating
profit margin
Earnings
before
income taxes Income taxes
Net earnings
for calculation
of diluted
earnings per
common share
Diluted net
earnings per
common
share 4
Reported (GAAP) $ 21,197 $ (8,786) 58.6 % $ 4,661 22.0 % $ 4,587 $ (902) $ 3,664 I $ 4.94
Amortization of acquisition-related
intangible assets A — — — 1,147 5.4 1,147 1,147 1.54
Fair value net (gains) losses on
investments B — — — — — 58 58 0.08
Separation costs C — — — 101 0.5 101 101 0.14
Impairments and other charges D — 14 0.1 54 0.3 54 54 0.07
Tax effect of the above adjustments F (259) (259) (0.35)
Discrete tax adjustments G 13 13 0.02
MCPS "as if converted" H — — — — — — — 21 —
Rounding — — (0.1) — (0.1) — — — —
Adjusted (Non-GAAP) $ 21,197 $ (8,772) 58.6 % $ 5,963 28.1 % $ 5,947 $ (1,148) $ 4,799 $ 6.44
Nine-Month Period Ended September 29, 2023
Sales
Selling,
general and
administrative
expenses
Selling,
general and
administrative
expenses as a
% of sales
Research and
development
expenses
Research and
development
expenses as a
% of sales
Nonoperating
income
(expense), net
(excluding
interest)
Interest
income
(expense), net
Reported (GAAP) $ 21,197 $ (6,486) (30.6) % $ (1,264) (6.0) % $ (52) $ (22)
Amortization of acquisition-related
intangible assets A — 1,147 5.4 — — — —
Fair value net (gains) losses on
investments B — — — — — 58 —
Separation costs C — 101 0.5 — — — —
Impairments and other charges D — 40 0.2 — — — —
Adjusted (Non-GAAP) $ 21,197 $ (5,198) (24.5) % $ (1,264) (6.0) % $ 6 $ (22)
4 Each of the per share amounts above have been calculated assuming the Mandatory Convertible Preferred Stock (“MCPS”) had been converted into shares of common stock. Net earnings per diluted
common share amounts for the relevant three-month period may not add to the year-to-date amounts due to rounding.
DANAHER CORPORATION
Other Non-GAAP Adjusted P&L Measures
($ in millions, except per share data)
10

-- 22 of 30 --

Nine-Month Period Ended September 30, 2022
Sales Cost of sales Gross profit
margin Operating
profit Operating
profit margin
Earnings
before
income taxes Income taxes
Net earnings
for calculation
of diluted
earnings per
common share
Diluted net
earnings per
common
share 4
Reported (GAAP) $ 23,102 $ (9,092) 60.6 % $ 6,392 27.7 % $ 6,099 $ (1,122) $ 4,913 I $ 6.67
Amortization of acquisition-related
intangible assets A — — — 1,120 4.8 1,120 1,120 1.50
Fair value net (gains) losses on
investments B — — — — — 186 186 0.25
Impairments and other charges D — 18 0.1 52 0.2 52 52 0.07
Loss on partial settlement of a defined
benefit plan E — — — — — 10 10 0.01
Tax effect of the above adjustments F (267) (267) (0.36)
Discrete tax adjustments G (52) (52) (0.07)
MCPS "as if converted" H — — — — — — — 64 0.01
Adjusted (Non-GAAP) $ 23,102 $ (9,074) 60.7 % $ 7,564 32.7 % $ 7,467 $ (1,441) $ 6,026 $ 8.08
Nine-Month Period Ended September 30, 2022
Sales
Selling,
general and
administrative
expenses
Selling,
general and
administrative
expenses as a
% of sales
Research and
development
expenses
Research and
development
expenses as
a % of sales
Nonoperating
income
(expense),
net
(excluding
interest)
Interest
income
(expense),
net
Reported (GAAP) $ 23,102 $ (6,326) (27.4) % $ (1,292) (5.6) % $ (158) $ (135)
Amortization of acquisition-related
intangible assets A — 1,120 4.8 — — — —
Fair value net (gains) losses on
investments B — — — — — 186 —
Impairments and other charges D — 34 0.1 — — — —
Loss on partial settlement of a defined
benefit plan E — — — — — 10 —
Rounding — — 0.1 — — — —
Adjusted (Non-GAAP) $ 23,102 $ (5,172) (22.4) % $ (1,292) (5.6) % $ 38 $ (135)
4 Each of the per share amounts above have been calculated assuming the Mandatory Convertible Preferred Stock (“MCPS”) had been converted into shares of common stock. Net earnings per diluted
common share amounts for the relevant three-month period may not add to the year-to-date amounts due to rounding.
DANAHER CORPORATION
Other Non-GAAP Adjusted P&L Measures
($ in millions, except per share data)
11

-- 23 of 30 --

A Amortization of acquisition-related intangible assets in the following historical periods (only the pretax amounts set forth below are reflected in the
amortization line item above):
Three-Month Period Ended Nine-Month Period Ended
September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022
Pretax $ 379 $ 361 $ 1,147 $ 1,120
After-tax 306 293 926 904
B Net (gains) losses on the Company's equity and limited partnership investments recorded in the following historical periods (only the pretax amounts set
forth below are reflected in the fair value net (gains) losses on investments line above):
Three-Month Period Ended Nine-Month Period Ended
September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022
Pretax $ 48 $ 64 $ 58 $ 186
After-tax 36 48 44 141
C Costs incurred in the three and nine-month periods ended September 29, 2023 related to preparation for the separation of the Company’s Environmental
& Applied Solutions business, primarily related to professional fees for legal, tax, finance, banking and information technology services and duplicative
general and administrative costs ($36 million and $101 million pretax as reported in this line item, and $31 million and $90 million after-tax, respectively).
D Impairment charges related to a trade name in the Environmental & Applied Solutions segment recorded in the three-month period ended September 29,
2023 ($6 million pretax as reported in this line item, $4 million after-tax). Impairment charges related to technology and other assets in the Biotechnology
segment and customer relationships and a trade name in the Environmental & Applied Solutions segment recorded in the nine-month period ended
September 29, 2023 ($54 million pretax as reported in this line item, $41 million after-tax). Impairment charges related to technology and customer
relationships in the Environmental & Applied Solutions segment recorded in the nine-month period ended September 30, 2022 ($9 million pretax as
reported in this line item, $7 million after-tax). Additionally, in the nine-month period ended September 30, 2022, charges incurred primarily related to
impairments of accounts receivable and inventory as well as accruals for contractual obligations in Russia ($43 million pretax as reported in this line item,
$40 million after-tax).
E Loss on a partial settlement of a defined benefit plan as a result of the transfer of a portion of the Company’s non-U.S. pension liabilities related to one
defined benefit plan to a third-party in the nine-month period ended September 30, 2022 ($10 million pretax as reported in this line item, $9 million after-
tax).
F This line item reflects the aggregate tax effect of all nontax adjustments reflected in the preceding line items of the table. In addition, the footnotes above
indicate the after-tax amount of each individual adjustment item. Danaher estimates the tax effect of each adjustment item by applying Danaher’s overall
estimated effective tax rate to the pretax amount, unless the nature of the item and/or the tax jurisdiction in which the item has been recorded requires
application of a specific tax rate or tax treatment, in which case the tax effect of such item is estimated by applying such specific tax rate or tax treatment.
The MCPS dividends are not tax deductible and therefore the tax effect of the adjustments does not include any tax impact of the MCPS dividends.
G There were no net discrete tax adjustments and other tax-related adjustments for the three-month period ended September 29, 2023, as discrete tax
benefits from excess tax benefits from stock-based compensation were offset by charges related to tax costs related to the separation of the
Environmental & Applied Solutions business and changes in estimates associated with prior period uncertain tax positions. Discrete tax adjustments and
other tax-related adjustments for the nine-month period ended September 29, 2023, include the impact of a net discrete tax loss of $13 million related
primarily to tax costs related to the separation of the Environmental & Applied Solutions business and tax costs related to legal and operational actions
taken to realign certain businesses and changes in estimates associated with prior period uncertain tax positions, partially offset by excess tax benefits
from stock-based compensation and interest on prior year tax refunds. Discrete tax adjustments and other tax-related adjustments for the three-month
period ended September 30, 2022, include the impact of net discrete tax benefits of $3 million related primarily to excess tax benefits from stock-based
DANAHER CORPORATION
Other Non-GAAP Adjusted P&L Measures
($ in millions, except per share data)
12

-- 24 of 30 --

compensation partially offset by changes in estimates associated with prior period uncertain tax positions. Discrete tax adjustments and other tax-related
adjustments for the nine-month period ended September 30, 2022, include the impact of net discrete tax benefits of $52 million related primarily to excess
tax benefits from stock-based compensation and changes in estimates associated with prior period uncertain tax positions.
H In March 2019, the Company issued $1.65 billion in aggregate liquidation preference of 4.75% MCPS Series A. In May 2020, the Company issued $1.72
billion in aggregate liquidation preference of 5.0% MCPS Series B. Dividends on the MCPS Series A and Series B were payable on a cumulative basis at
an annual rate of 4.75% and 5.0%, respectively, on the liquidation preference of $1,000 per share. Each share of MCPS Series A converted on April 15,
2022 into 6.6632 shares of Danaher’s common stock. Each share of MCPS Series B converted on April 17, 2023 into 5.0175 shares of Danaher’s
common stock. For the calculation of net earnings per common share, the impact of the dilutive MCPS is calculated under the “if-converted” method and
the related MCPS dividends are excluded. For the purposes of calculating adjusted earnings per common share, the Company has excluded the paid
MCPS cash dividends and assumed the “if-converted” method of share dilution (the incremental shares of common stock deemed outstanding applying
the “if-converted” method of calculating share dilution only with respect to any MCPS the conversion of which would be dilutive in the particular period are
referred to as the “Converted Shares”) for any MCPS that were anti-dilutive for the given period. For additional information about the impact of the MCPS
on the calculation of diluted EPS, see note 5 in the Average and Adjusted Average Common Stock and Common Equivalent Diluted Shares Outstanding
table below.
I Net earnings for calculation of diluted earnings per common share is summarized as follows:
Three-Month Period Ended Nine-Month Period Ended
September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022
Net earnings $ 1,129 $ 1,572 $ 3,685 $ 4,977
MCPS dividends — (21) (21) (84)
Net earnings attributable to common stockholders for Basic EPS 1,129 1,551 3,664 4,893
Adjustment for MCPS dividends for dilutive MCPS — — — 20
Net earnings attributable to common stockholders after assumed conversions
for Diluted EPS $ 1,129 $ 1,551 $ 3,664 $ 4,913
DANAHER CORPORATION
Other Non-GAAP Adjusted P&L Measures
($ in millions, except per share data)
13

-- 25 of 30 --

Forecasted
Three-Month Period Ended Nine-Month Period Ended Three-Month
Period Ending
December 31, 2023 Year Ending
December 31, 2023	September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022
Average common stock and common equivalent
shares outstanding - diluted (GAAP) 5 745.9 737.4 742.1 737.0 748.7 743.8
Converted shares 6 — 8.6 3.4 8.6 — 2.5
Adjusted average common stock and common
equivalent shares outstanding - diluted (non-
GAAP) 745.9 746.0 745.5 745.6 748.7 746.3
5 The impact of the MCPS Series B calculated under the if-converted method was anti-dilutive for the nine-month period ended September 29, 2023 and the three and nine-month periods ended
September 30, 2022, and as such 3.4 million shares for the nine-month period ended September 29, 2023 and 8.6 million for both the three and nine-month periods ended September 30, 2022
underlying the MCPS Series B were excluded from the calculation of diluted EPS and the related MCPS Series B dividends of $21 million for the nine-month period ended September 29, 2023
and $21 million and $64 million for the three and nine-month periods ended September 30, 2022, respectively, were included in the calculation of net earnings for diluted EPS. As of April 17,
2023, all outstanding shares of the MCPS Series B converted into 8.6 million shares of the Company’s common stock.
The impact of the MCPS Series A calculated under the if-converted method was dilutive for the nine-month period ended September 30, 2022, and as such 4.0 million shares underlying the
MCPS Series A were included in the calculation of diluted EPS. The related MCPS Series A dividends of $20 million for the nine-month period ended September 30, 2022 were excluded from
the calculation of net earnings for diluted EPS. On April 15, 2022, all outstanding shares of the MCPS Series A converted into 11.0 million shares of the Company’s common stock.
Additionally, for the year ending December 31, 2023, the impact of the MCPS Series B calculated under the if-converted method is forecasted to be anti-dilutive and as such, approximately 2.5
million shares underlying the MCPS Series B are excluded from the calculation of diluted EPS.
6 The number of converted shares assumes the conversion of all MCPS and issuance of the underlying shares applying the “if-converted” method of accounting and using the actual conversion
rates for the nine-month period ended September 29, 2023 and an average 20 trading-day trailing Volume Weighted Average Price of $274.64 as of September 30, 2022.
DANAHER CORPORATION
Average and Adjusted Average Common Stock and Common Equivalent Diluted Shares Outstanding
(shares in millions)
14

-- 26 of 30 --

Segments
Total Company Biotechnology Life Sciences Diagnostics
Environmental &
Applied
Solutions
Three-Month Period Ended September 30, 2022 Operating Profit Margins
(GAAP) 26.30 % 33.70 % 20.50 % 28.40 % 23.70 %
Third quarter 2023 impact from operating profit margins of businesses that
have been owned for less than one year (0.05) 0.05 (0.25) (0.05) 0.10
Third quarter 2023 impairment charges related to a trade name in the
Environmental & Applied Solutions segment (0.10) — — — (0.50)
Third quarter 2023 costs incurred related to preparation for the separation of
the Company's Environmental & Applied Solutions business (0.55) — — — —
Year-over-year core operating profit margin changes for the third quarter
2023 (defined as all year-over-year operating profit margin changes other
than the changes identified in the line items above) (non-GAAP) (4.70) (8.65) (1.95) (4.45) (0.40)
Three-Month Period Ended September 29, 2023 Operating Profit Margins
(GAAP) 20.90 % 25.10 % 18.30 % 23.90 % 22.90 %
Segments
Total Company Biotechnology Life Sciences Diagnostics
Environmental &
Applied
Solutions
Nine-Month Period Ended September 30, 2022 Operating Profit Margins
(GAAP) 27.70 % 35.40 % 20.10 % 31.00 % 23.10 %
First nine months of 2023 impact from operating profit margins of
businesses that have been owned for less than one year or were disposed
of during such period and did not qualify as discontinued operations (0.10) (0.10) (0.35) (0.05) 0.10
Second quarter 2023 impairment charges related to technology and other
assets in the Biotechnology segment and customer relationships in the
Environmental & Applied Solutions segment and third quarter 2023
impairment charge related to a trade name in the Environmental & Applied
Solutions segment, net of a second quarter 2022 impairment charge related
to technology and customer relationships in the Environmental & Applied
Solutions segment (0.20) (0.80) — — (0.05)
First nine months of 2023 costs incurred related to preparation for the
separation of the Company's Environmental & Applied Solutions business (0.45) — — — —
First nine months of 2022 impairments of accounts receivable and inventory
as well as accruals for contractual obligations in Russia 0.15 0.20 0.50 0.05 —
Year-over-year core operating profit margin changes for first nine months
of 2023 (defined as all year-over-year operating profit margin changes
other than the changes identified in the line items above) (non-GAAP) (5.10) (7.10) (1.55) (7.10) 0.75
Nine-Month Period Ended September 29, 2023 Operating Profit Margins
(GAAP) 22.00 % 27.60 % 18.70 % 23.90 % 23.90 %
DANAHER CORPORATION
Operating Profit Margins and Year-Over-Year Core Operating Profit Margin Changes
15

-- 27 of 30 --

Three-Month Period Ended Year-over-Year
Change
Nine-Month Period Ended Year-over-Year
Change	September 29, 2023 September 30, 2022 September 29, 2023 September 30, 2022
Total Cash Flow:
Net cash provided by operating activities (GAAP) $ 1,672 $ 2,010 $ 5,545 $ 5,978
Total cash used in investing activities (GAAP) $ (329) $ (515) $ (1,064) $ (1,418)
Total cash provided by (used in) financing activities
(GAAP) $ 2,443 $ (230) $ 1,973 $ (1,664)
Free Cash Flow:
Net cash provided by operating activities (GAAP) $ 1,672 $ 2,010 ~ (17.0) % $ 5,545 $ 5,978 ~ (7.0) %
Less: payments for additions to property, plant &
equipment (capital expenditures) (GAAP) (365) (277) (981) (823)
Plus: proceeds from sales of property, plant &
equipment (capital disposals) (GAAP) 4 — 8 9
Free cash flow (non-GAAP) $ 1,311 $ 1,733 ~ (24.5) % $ 4,572 $ 5,164 ~ (11.5) %
Operating Cash Flow to Net Earnings Ratio
(GAAP)
Net cash provided by operating activities (GAAP) $ 1,672 $ 2,010 $ 5,545 $ 5,978
Net earnings (GAAP) 1,129 1,572 3,685 4,977
Operating cash flow to net earnings conversion ratio 1.48 1.28 1.50 1.20
Free Cash Flow to Net Earnings Conversion Ratio:
Free cash flow from above (non-GAAP) $ 1,311 $ 1,733 $ 4,572 $ 5,164
Net earnings (GAAP) 1,129 1,572 3,685 4,977
Free cash flow to net earnings conversion ratio (non-
GAAP) 1.16 1.10 1.24 1.04
We define free cash flow as operating cash flows, less payments for additions to property, plant and equipment (“capital expenditures”) plus the proceeds from sales of plant, property and
equipment (“capital disposals”).
DANAHER CORPORATION
Cash Flow, Free Cash Flow, Operating Cash Flow to Net Earnings Ratio and Free Cash Flow to Net Earnings Conversion Ratio
($ in millions)
16

-- 28 of 30 --

Each of the non-GAAP measures set forth above should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measure,
and may not be comparable to similarly titled measures reported by other companies. Management believes that these measures provide useful information to
investors by offering additional ways of viewing Danaher Corporation’s (“Danaher” or the “Company”) results that, when reconciled to the corresponding GAAP
measure, help our investors:
• with respect to the profitability-related non-GAAP measures, understand the long-term profitability trends of our business and compare our profitability to
prior and future periods and to our peers;
• with respect to core sales and related non-GAAP sales measures, identify underlying growth trends in our business and compare our sales performance
with prior and future periods and to our peers; and
• with respect to free cash flow and related non-GAAP cash flow measures (the “FCF Measure”), understand Danaher’s ability to generate cash without
external financings, strengthen its balance sheet, invest in its business and grow its business through acquisitions and other strategic opportunities
(although a limitation of free cash flow is that it does not take into account the Company’s debt service requirements and other non-discretionary
expenditures, and as a result the entire free cash flow amount is not necessarily available for discretionary expenditures).
We expect overall demand for the Company’s COVID-19 related products to continue moderating as the pandemic has evolved toward endemic status. We
believe certain demand for the Company’s products that support COVID-19 related vaccines and therapeutics (including initiatives that seek to prevent or mitigate
similar, future pandemics) and COVID-19 testing will continue, though that demand will likely be uncertain and will vary from period to period. At the beginning of
2022, the Company believed that on a relative basis, the level of ongoing demand for products supporting COVID-19 testing would be subject to more fluctuations
in demand than the level of demand for products supporting COVID-19 related vaccines and therapeutics, due in part to expected COVID-19 case levels,
vaccination rates and use of therapies. However, as a result of lower vaccination rates and the spread of less severe variants of the virus, 2022 demand for the
Company’s products supporting COVID-19 related vaccines and therapeutics fluctuated and declined more than anticipated at the beginning of the year.
Therefore, beginning with the first quarter of 2023, we have revised the definition of “base business core sales growth” on a basis that not only excludes revenues
related to COVID-19 testing but also excludes revenues from products that support COVID-19 related vaccines and therapeutics. We believe this adjusted
definition of “base business core sales growth” provides more useful information to investors by facilitating period-to-period comparisons of our financial
performance and identifying underlying growth trends in the Company’s business that otherwise may be obscured by fluctuations in demand for COVID-19 related
products.
Management uses the non-GAAP measures referenced above to measure the Company’s operating and financial performance, and uses core sales and non-
GAAP measures similar to Adjusted Diluted Net Earnings Per Common Share and the FCF Measure in the Company’s executive compensation program.
• The items excluded from the non-GAAP measures set forth above have been excluded for the following reasons:
◦ Amortization of Intangible Assets: We exclude the amortization of acquisition-related intangible assets because the amount and timing of such
charges are significantly impacted by the timing, size, number and nature of the acquisitions we consummate. While we have a history of
significant acquisition activity we do not acquire businesses on a predictable cycle, and the amount of an acquisition’s purchase price allocated to
intangible assets and related amortization term are unique to each acquisition and can vary significantly from acquisition to acquisition. Exclusion
of this amortization expense facilitates more consistent comparisons of operating results over time between our newly acquired and long-held
businesses, and with both acquisitive and non-acquisitive peer companies. We believe however that it is important for investors to understand
that such intangible assets contribute to sales generation and that intangible asset amortization related to past acquisitions will recur in future
periods until such intangible assets have been fully amortized.
◦ Restructuring Charges: We exclude costs incurred pursuant to discrete restructuring plans that are fundamentally different (in terms of the size,
strategic nature and planning requirements, as well as the inconsistent frequency, of such plans) from the ongoing productivity improvements that
result from application of the Danaher Business System. Because these restructuring plans are incremental to the core activities that arise in the
ordinary course of our business and we believe are not indicative of Danaher’s ongoing operating costs in a given period, we exclude these costs
to facilitate a more consistent comparison of operating results over time.
DANAHER CORPORATION
Statement Regarding Non-GAAP Measures
17

-- 29 of 30 --

◦ Other Adjustments: With respect to the other items excluded from Adjusted Diluted Net Earnings Per Common Share, we exclude these items
because they are of a nature and/or size that occur with inconsistent frequency, occur for reasons that may be unrelated to Danaher's commercial
performance during the period and/or we believe that such items may obscure underlying business trends and make comparisons of long-term
performance difficult. For example, we excluded the first quarter 2022 charge for asset impairments, accruals for contractual obligations and
similar items related to our Russia operations because, even though it is possible we could incur additional charges in the future, we do not
believe these charges are indicative of Danaher’s ongoing operating costs.
• With respect to adjusted average common stock and common equivalent shares outstanding, Danaher’s Mandatory Convertible Preferred Stock (“MCPS”)
Series A converted into Danaher common stock on April 15, 2022 and the MCPS Series B mandatorily converted into Danaher common stock on the
mandatory conversion date of April 17, 2023 (unless converted or redeemed earlier in accordance with the terms of the applicable certificate of
designations). With respect to the calculation of Adjusted Diluted Net Earnings Per Common Share, we apply the “if converted” method of share dilution to
the MCPS Series A and B in all applicable periods irrespective of whether such preferred shares would be dilutive or anti-dilutive in the period. We believe
this presentation provides useful information to investors by helping them understand the net impact on Danaher’s earnings per share-related measures
irrespective of the period.
• With respect to core operating profit margin changes, in addition to the explanation set forth in the bullets above relating to "restructuring charges” and
“other adjustments”, we exclude the impact of businesses owned for less than one year (or disposed of during such period and not treated as discontinued
operations) because the timing, size, number and nature of such transactions can vary significantly from period to period and may obscure underlying
business trends and make comparisons of long-term performance difficult.
• We calculate adjusted EBITDA by adding to operating profit amounts equal to depreciation and amortization and making the other adjustments reflected in
the applicable tables above, which allows us to calculate and disclose such measure by segment. Given Danaher’s diversification, we believe this helps
our investors compare the profitability of our individual segments to peer companies with like business lines.
• With respect to core sales related measures, (1) we exclude the impact of currency translation because it is not under management’s control, is subject to
volatility and can obscure underlying business trends, and (2) we exclude the effect of acquisitions and divested product lines because the timing, size,
number and nature of such transactions can vary significantly from period-to-period and between us and our peers, which we believe may obscure
underlying business trends and make comparisons of long-term performance difficult.
• With respect to the FCF Measure, we exclude payments for additions to property, plant and equipment (net of the proceeds from capital disposals) to
demonstrate the amount of operating cash flow for the period that remains after accounting for the Company’s capital expenditure requirements.
The Company provides forecasted sales only on a non-GAAP basis because of the difficulty in estimating the other components of GAAP revenue, such as
currency translation, acquisitions and divested product lines. Additionally, we do not reconcile adjusted operating profit margin (or components thereof) to the
comparable GAAP measures because of the difficulty in estimating the other components (in addition to items identified in the prior sentence) such as investment
gains and losses, impairments and separation costs, which would be reflected in any forecasted GAAP operating profit.
DANAHER CORPORATION
Statement Regarding Non-GAAP Measures
18

-- 30 of 30 --